Anemone toxin inhibits KV1.3

A board to discuss future MS therapies in early stage (Phase I or II) trials.
Post Reply
User avatar
NHE
Volunteer Moderator
Posts: 6427
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Anemone toxin inhibits KV1.3

Post by NHE »

The Alliance for Children's Therapeutics in collaboration with Dr. Anne Stevens of Seattle Children's Hospital and Kineta Biotech are developing a synthetic protein known as Shk-186. Based on a toxin from the Sun Anemone, Shk-186 inhibits the potassium channel KV1.3 in effector memory T cells and blocks the proinflammatory cytokine cascade leading to autoimmunity.

http://www.childrenstherapeutics.org/treatments.html

http://www.kinetabio.com/autoimmune.html

http://www.seattlechildrens.org/researc ... evens-lab/
Post Reply

Return to “Drug Pipeline”